Rekrutierung von Patienten – schnell, fair, qualitätvoll
emovis ist nicht nur bekannt für seine hohen Rekrutierungszahlen. Sondern vor allem auch für die Einhaltung bzw. das Übertreffen von prognostizierten Rekrutierungsraten an Studienteilnehmern. Der Grund: zum einen zeigt emovis viel Erfahrung und Innovationsbereitschaft in der Rekrutierung von Patienten, zum andern hat die emovis-Geschäftsführung schlicht die Gewohnheit, Rekrutierungszahlen konservativ zu schätzen. Für emovis ein Gebot der Fairness. Nicht wenige Auftraggeber waren bis dato schon verblüfft – und erfreut.
Suche nach vergangenen Studien und Rekrutierungszahlen
| Start | Sponsor | Auftraggeber | Zeitraum | Rekrutiert | Studiennummer |
|---|---|---|---|---|---|
| 2017 | Schlafstörungen ab 55 Jahren | Eisai Inc. | 10 Monate | 93 | EudraCT-2015-004347-39 |
| 2017 | Reizdarmsyndrom | Dr. Willmar Schwabe | 9 Monate | 23 | EudraCT-2014-004702-14 |
| 2017 | MDD | Janssen-Cilag | 11 Monate | 12 | EudraCT-2016-001929-14 |
| 2017 | Osteoarthritis | Astellas | 1 Monat | 22 | EudraCT-2014-004996-22 |
| 2017 | Prädiabetes | Glycemicon | 13 Monate | 60 | |
| 2017 | Impfung gegen Clostridium difficile | Pfizer Pharma | 16 Monate | 26 | |
| 2016 | Harnwegsinfektion | Repha | 20 Monate | 22 | |
| 2017 | Allergrische Rhinitis | ALK-Abelló | 1 Monat | 8 | EudraCT-2017-000971-97 |
| 2017 | COPD | Astra Zeneca, Pearl | 1 Monat | 18 | EudraCT-2016-000154-34 |
| 2017 | COPD | Verona Pharma | 3 Monate | 16 | EudraCT-2016-005205-40 |
| 2017 | Akute Grippe | Medicago | 2 Monate | 92 | |
| 2018 | Frühstadium Alzheimer-Erkrankung | Eisai Inc. | 9 Monate | 13 | |
| 2018 | Schlafstörung | Idorsia | 5 Monate | 76 | |
| 2018 | Akute Grippe | Medicago | 2 Wochen | 38 | |
| 2018 | Osteoarthrose | Regeneron | 2 Wochen | 4 | |
| 2018 | Onychomykose (Nagelpilz) | Moberg Pharma | 5 Monate | 71 | |
| 2018 | Schlafstörung | Janssen Research | 4 Monate | 9 | |
| 2018 | Prämenstruelles Syndrom | Asarina | 6 Monate | 24 | |
| 2018 | Uterusmyom | Bayer AG | 8 Monate | 8 | |
| 2016 | Onychomykose (Nagelpilz) | Almirall | 4 Monate | 59 | EudraCT-2015-000561-31 |
| 2015 | Osteoarthrose | Regeneron | 6 monate | 48 | |
| 2015 | COPD | Novartis | 4 Monate | 15 | |
| 2014 | Diabetes mellitus Typ 2 | Hanmi | 5 Monate | 1 | EudraCT-2013-004250-13 |
| 2013 | Depression | Allergan | 12 Monate | 25 | EudraCT- 2012-001950-25 |
| 2012 | COPD | Allergan, Almirall, Astra Zeneca | 6 Monate | 27 | EudraCT-2011-001524-38 |
| 2011 | COPD | Glaxo Smith Kline Research & Development Ltd. | 6 Monate | 20 | EudraCT-2010-021802-39 |
| 2008 | Generalisierte Angsterkrankung | H. Lundbeck | 3 Monate | 10 | EudraCT-2008-001766-90 |
| 2008 | Depression | Takeda | 8 Monate | 28 | EudraCT-2008-001580-11 |
| 2008 | Diabetes mellitus Typ 2 | Lilly Deutschland | 4 monate | 4 | EudraCT -2008-004207-63 |
| 2018 | Migräne | Merck Sharp & Dohme Corp. | 2 Monate | 55 | |
| 2006 | Metrorrhagie | Bayer AG | 6 Monate | 11 | EudraCT- 2005-004340-32 |
| 2006 | Morbus Parkinson | Axxonis | 2 Monate | 1 | EudraCT-2006-003732-30 |
| 2006 | Restless Legs Syndrom | Boehringer Ingelheim | 3 Monate | 21 | EudraCT-2005-006128-13 |
| 2003 | Diabetes mellitus Typ 2 | Glaxo Smith Kline Research & Development Ltd. | 8 Monate | 5 | |
| 2009 | Alzheimer Demenz | H. Lundbeck | 9 Monate | 4 | |
| 2017 | Psoriasis | Novartis | 4 Monate | 4 | EudraCT-2015-005170-38 |
| 2017 | Dyslipidämie | Esperion Therapeutics | 9 Monate | 4 | |
| 2012 | Alzheimer Demenz | Avraham Pharmaceuticals Ltd. | 17 Monate | 32 | EudraCT-2010-021926-37 |
| 2015 | Depression | Alkermes | 5 Monate | 14 | EudraCT-2014-000380-41 |
| 2017 | Migräne | CoLucid Pharmaceuticals | 4 Monate | 17 | EudraCT-2015-005689-40 |
| 2000 | Depression | Boehringer Ingelheim | 12 Monate | 60 | |
| 2000 | Soziale Phobie | Solvay | 3 Monate | 23 | |
| 2001 | Panikstörung | Pfizer Pharma | 3 Monate | 4 | |
| 2001 | Panikstörung | Wyeth | 12 Monate | 49 | |
| 2001 | Depression | Servier Forschung und Pharma-Entwicklung | 3 Monate | 9 | |
| 2002 | Soziale Phobie | Glaxo Smith Kline Research & Development Ltd. | 3 Monate | 25 | |
| 2002 | Generalisierte Angsterkrankung | Orion Pharma | 5 Monate | 35 | |
| 2002 | Depression | Dr. Willmar Schwabe | 10 Monate | 13 | |
| 2002 | Schizophrenie | Janssen-Cilag | 6 Monate | 7 | |
| 2002 | Restless Legs Syndrom | Glaxo Smith Kline Research & Development Ltd. | 2 Wochen | 9 | |
| 2002 | Restless Legs Syndrom | Glaxo Smith Kline Research & Development Ltd. | 3 Monate | 16 | |
| 2002 | Restless Legs Syndrom | Boehringer Ingelheim | 3 Monate | 35 | |
| 2002 | Migräne | Glaxo Smith Kline Research & Development Ltd. | 4 Monate | 55 | |
| 2002 | Migräne | Bayer AG | 3 Monate | 10 | |
| 2002 | Depression | Servier Forschung und Pharma-Entwicklung | 3 Monate | 22 | |
| 2003 | Raucherentwöhnung | Glaxo Smith Kline Research & Development Ltd. | 4 Tage | 101 | |
| 2003 | Alzheimer Demenz | Janssen-Cilag | 4 Monate | 5 | |
| 2003 | Depression | Servier Forschung und Pharma-Entwicklung | 2 Monate | 24 | |
| 2003 | Restless Legs Syndrom | UCB S.A. | 6 Wochen | 32 | |
| 2003 | Depression | H. Lundbeck | 7 Monate | 21 | |
| 2003 | Alzheimer Demenz | Sanofi-Synthelabo | 15 Monate | 15 | |
| 2003 | Depression | Dr. Willmar Schwabe | 14 Monate | 58 | |
| 2004 | Restless Legs Syndrom | Imerem, Schwarz BioSciences | 6 Monate | 20 | EudraCT-2005-000428-18 |
| 2004 | Diabetische Polyneuropathie | INC Research, Schwarz BioSciences | 4 Monate | 19 | |
| 2004 | Restless Legs Syndrom | Boehringer Ingelheim | 3 Monate | 49 | |
| 2004 | Depression | Lilly Deutschland | 3 Monate | 50 | |
| 2004 | Alzheimer Demenz | Glaxo Smith Kline Research & Development Ltd. | 8 Monate | 2 | EudraCT-2004-000985-12 |
| 2004 | Depression | Imerem, Schwarz Pharma | 6 Monate | 5 | |
| 2004 | Depression | Wyeth | 3 Monate | 27 | EudraCT-2004-000562-13 |
| 2004 | Depression | Glaxo Smith Kline Research & Development Ltd. | 8 Monate | 31 | |
| 2004 | Reizdarmsyndrom | Glaxo Smith Kline Research & Development Ltd. | 5 Monate | 49 | EudraCT-2004-000848-24 |
| 2004 | Soziale Phobie | Glaxo Smith Kline Research & Development Ltd. | 5 Monate | 35 | EudraCT-2004-000848-24 |
| 2004 | Generalisierte Angsterkrankung | Lilly Deutschland | 10 Monate | 14 | |
| 2005 | Depression | Glaxo Smith Kline Research & Development Ltd. | 2 Monate | 1 | EudraCT-2004-003803-19 |
| 2005 | Reizdarmsyndrom | Yamanouchi Pharma | 2 Monate | 12 | EudraCT-2004-003880-61 |
| 2005 | Generalisierte Angsterkrankung | Lilly Deutschland | 8 Monate | 17 | EudraCT-2004-002626-22 |
| 2005 | Depression | Boehringer Ingelheim | 7 Monate | 9 | |
| 2005 | Prämenstruelles Syndrom | Wyeth | 8 Monate | 3 | EudraCT-2004-005173-27 |
| 2005 | Bronchitis | Bionorica | 2 Wochen | 3 | EudraCT-2005-003249-15 |
| 2005 | Panikstörung | Elbion | 1 Monat | 12 | EudraCT-2005-005708-17 |
| 2006 | Restless Legs Syndrom | Imerem | 2 Monate | 12 | |
| 2006 | Depression | Glaxo Smith Kline Research & Development Ltd. | 3 Monate | 21 | EudraCT-2006-001877-13 |
| 2006 | Depression | Servier Forschung und Pharma-Entwicklung | 3 Monate | 46 | EudraCT-2004-004009-10 |
| 2006 | Depression | Sanofi-Aventis | 4 Monate | 42 | EudraCT - 2004-002327-41 |
| 2006 | Restless Legs Syndrom | Imerem, Schwarz Pharma | 2 Monate | 11 | EudraCT-2004-001589-42 |
| 2006 | Schlafstörung | Sanofi-Aventis | 18 Monate | 31 | EudraCT- 2005-003082-16 |
| 2006 | Restless Legs Syndrom | Axxonis | 10 Monate | 26 | EudraCT-2004-001589-42 |
| 2006 | Generalisierte Angsterkrankung | Astra Zeneca | 9 Monate | 7 | EudraCT- 2005-005055-18 |
| 2006 | Depression | Astra Zeneca | 4 Monate | 13 | EudraCT- 2005-003745-14 |
| 2006 | Reizdarmsyndrom | Glaxo Smith Kline Research & Development Ltd. | 3 Monate | 28 | |
| 2006 | Restless Legs Syndrom | Glaxo Smith Kline Research & Development Ltd. | 4 Monate | 3 | |
| 2006 | Restless Legs Syndrom | Boehringer Ingelheim | 7 Monate | 21 | EudraCT-2005-005225-54 |
| 2006 | Hypertonie | Astra Zeneca | 6 Monate | 50 | EudraCT -2005-005718-19 |
| 2006 | Soziale Phobie | Glaxo Smith Kline Research & Development Ltd. | 5 Monate | 16 | EudraCT- 2006-003597-10 |
| 2007 | Depression | Pierre Fabre | 5 Monate | 11 | EudraCT-2006-002404-34 |
| 2007 | Generalisierte Angsterkrankung | Sanofi-Aventis | 6 Monate | 16 | EudraCT 2006-002253-71 |
| 2007 | Migräne | MSD | 5 Monate | 35 | EudraCT-2006-006187-35 |
| 2007 | Restless Legs Syndrom | Boehringer Ingelheim | 4 Monate | 34 | EudraCT-2006-006431-42 |
| 2007 | Hypertonie | DaiichiSankyo Deutschland | 19 Monate | 19 | EudraCT-2008-008260-28 |
| 2007 | Post-Zoster-Neuralgie | Grünenthal | 4 Monate | 8 | |
| 2007 | Diabetische Polyneuropathie | Grünenthal | 4 Monate | 8 | EudraCT-2006-003132-29 |
| 2007 | Morbus Parkinson | Imerem | 3 Monate | 1 | |
| 2007 | Diabetische Polyneuropathie | Swedish Orphan | 2 Monate | 1 | EudraCT- 2006-004007-19 |
| 2007 | Schlafstörung | Sanofi-Aventis | 12 Monate | 14 | EudraCT-2006-006677-25 |
| 2007 | Depression | Servier Forschung und Pharma-Entwicklung | 10 Monate | 16 | EudraCT-2006-004716-48 |
| 2007 | Depression | Sanofi-Aventis | 10 Monate | 36 | EudraCT-2004-002328-16 |
| 2007 | Depression | Glaxo Smith Kline Research & Development Ltd. | 10 Monate | 36 | EudraCT-2005-003400-11 |
| 2007 | Sexuelle Disfunktion | Boehringer Ingelheim | 11 Monate | 60 | EudraCT-2007-000032-68 |
| 2008 | Hypertonie | Takeda | 2 Monate | 10 | EudraCT-2007-002583-10 |
| 2008 | Fettstoffwechselstörung | MSD | 2 Monate | 33 | EudraCT 2011-001007-12 |
| 2008 | Sexuelle Disfunktion | Bayer AG | 4 Monate | 13 | Eudract-2006-004397-27 |
| 2008 | Depression | H. Lundbeck | 6 Monate | 30 | EudraCT-2008-001580-11 |
| 2008 | Diabetes mellitus Typ 2 | MSD | 1 Monat | 4 | EudraCT-2007-000145-35 |
| 2008 | Depression | Sanofi-Aventis | 6 Monate | 29 | EudraCT-2004-002328-16 |
| 2008 | Rückenschmerzen | Lilly Deutschland | 6 Monate | 12 | EudraCT-2006-003484-31 |
| 2008 | Migräne | MSD | 3 Monate | 55 | EudraCT-2006-004257-14 |
| 2008 | Überaktive Blase | Pfizer Pharma | 4 Monate | 18 | EudraCT-2004-000476-13 |
| 2008 | Reizdarmsyndrom | Menarini | 3 Monate | 24 | EudraCT-2008-000214-71 |
| 2008 | Impfung | Glaxo Smith Kline Research & Development Ltd. | 1 Monat | 44 | |
| 2008 | Alzheimer Demenz | IFE Europe | 1 Monat | 3 | EudraCT-2008-002758-39 |
| 2008 | Generalisierte Angsterkrankung | Takeda | 2 Monate | 7 | EudraCT-2008-001766-90 |
| 2008 | Hypertonie | Novartis | 4 Monate | 17 | EudraCT- 2006-006068-44 |
| 2008 | Impfung | MSD | 8 Monate | 844 | EudraCT-2007-004020-20 |
| 2009 | Diabetes mellitus Typ 2 | Lilly Deutschland | 2 Monate | 4 | EudraCT-2009-009889-13 |
| 2009 | Schlafstörung | Glaxo Smith Kline Research & Development Ltd. | 2 Monate | 29 | EudraCT-2008-006345-72 |
| 2009 | Depression | Takeda | 1 Monat | 49 | EudraCT-2008-001581-91 |
| 2009 | Alkoholabhängigkeit | Pierrell Research | 15 Monate | 28 | EudraCT-2007-002315-92 |
| 2009 | Osteoarthrose | Lilly Deutschland | 4 Monate | 12 | EudraCT-2009-010008-27 |
| 2009 | Diabetes mellitus Typ 2 | Boehringer Ingelheim | 8 Monate | 2 | EudraCT-2008-008296-33 |
| 2009 | Restless Legs Syndrom | Pfizer Pharma | 6 Monate | 16 | EudraCT-2008-005889-32 |
| 2009 | Diabetes mellitus Typ 2 | Novartis | 7 Monate | 6 | EudraCT-2008-002758-39 |
| 2009 | Alzheimer Demenz | Servier Forschung und Pharma-Entwicklung | 7 Monate | 7 | |
| 2009 | Depression | H. Lundbeck | 2 Monate | 6 | EudraCT-2007-001871-13 |
| 2009 | Alzheimer Demenz | H. Lundbeck | 7 Monate | 10 | |
| 2009 | Verhütungsmittel | Bayer AG | 8 Monate | 148 | EudraCT-2009-009177-10 |
| 2009 | Alkoholabhängigkeit | H. Lundbeck | 10 Monate | 121 | EudraCT-2007-002315-92 |
| 2010 | Depression | Glaxo Smith Kline Research & Development Ltd. | 4 Monate | 22 | EudraCT- 2009-010339-42 |
| 2010 | Alzheimer Demenz | Lilly Deutschland | 9 Monate | 4 | EudraCT-2008-002758-39 |
| 2010 | Depression | Sanofi-Aventis | 7 Monate | 33 | EudraCT-2009-010339-42 |
| 2010 | Alzheimer Demenz | JSW Lifescience | 6 Monate | 4 | |
| 2010 | Obstipation bei Männern | Shire-Movetis | 32 Monate | 16 | EudraCT-2009-015719-42 |
| 2010 | Migräne | Symbicort, Merck Sharp & Dohme Corp. | 1 Monat | 27 | EudraCT-2010-019288-13 |
| 2010 | Depression | Analyze & Realize, Leiber | 5 Monate | 95 | |
| 2010 | Impfung | Sanofi-Pasteuer MSD | 2 Monate | 108 | EudraCT-2010-021068-13 |
| 2010 | Impfung | Glaxo Smith Kline Research & Development Ltd. | 2 Monate | 40 | |
| 2010 | Erkältungsprophylaxe | Analyze & Realize, Leiber | 1 Monat | 60 | |
| 2011 | Diabetes mellitus Typ 2 | Boehringer Ingelheim | 15 Monate | 18 | EudraCT-2010-021375-92 |
| 2011 | Stressbewältigung | Dr. Willmar Schwabe | 4 Monate | 50 | EudraCT- 2010-022114-12 |
| 2011 | Depression | Astra Zeneca | 5 Monate | 18 | EudraCT-2010-019925-33 |
| 2011 | ADHS bei Erwachsenen | Novartis | 4 Monate | 70 | EudraCT-2011-004668-31 |
| 2011 | Hypertonie | Servier Forschung und Pharma-Entwicklung | 6 Monate | 25 | EudraCT- 2010-020945-28 |
| 2011 | Chronisch obstruktive Lungenerkrankung | Glaxo Smith Kline Research & Development Ltd. | 9 Monate | 21 | EudraCT-2010-021802-39 |
| 2011 | Depression | Takeda | 5 Monate | 46 | EudraCT- 2011-005298-22 |
| 2011 | Diabetes mellitus Typ 2 | MetaCure Germany | 10 Monate | 3 | EudraCT- 2010-020945-28 |
| 2011 | Neurasthenie | WELEDA AG | 9 Monate | 201 | EudraCT- 2010-024189-23 |
| 2011 | Venöse Insuffizienz | OM Pharma (Vifor Pharma) | 4 Monate | 9 | EudraCT-2009-013391-44 |
| 2011 | Restless Legs Syndrom | UCB S.A. | 4 Monate | 47 | EudraCT- 2011-000053-23 |
| 2011 | Alzheimer Demenz | Genetech | 4 Monate | 6 | EudraCT-2010-021926-37 |
| 2011 | ADHS bei Kindern | Shire | 7 Monate | 10 | EudraCT-2010-018579-12 |
| 2011 | Alzheimer Demenz | Avraham Pharmaceuticals Ltd. | 17 Monate | 32 | EudraCT-2010-021926-37 |
| 2012 | Reizdarmsyndrom | Laves Arzneimittel | 2 Jahre | 65 | |
| 2012 | Chronisch obstruktive Lungenerkrankung | Almirall | 5 Monate | 27 | EudraCT-2011-001524-38 |
| 2012 | Raucherentwöhnung | Pfizer Pharma | 2 Jahre | 371 | EudraCT- 2010-022914-15 |
| 2012 | Depression | Shire Development LLC | 12 Monate | 44 | EudraCT-2011-003018-17 |
| 2012 | Depression | MSD | 10 Monate | 5 | EudraCT-2011-005200-15 |
| 2012 | Depression | H. Lundbeck | 8 Monate | 19 | EudraCT-2012-001380-76 |
| 2013 | Binge Eating Disorder | Shire Development LLC | 2 Monate | 2 | Eudra CT-2012-003310-14 |
| 2013 | Chronisch obstruktive Lungenerkrankung | Glaxo Smith Kline Research & Development Ltd. | 1 Woche | 2 | EudraCT-2011-001644-29 |
| 2013 | Verstopfung | Ferring Pharmaceuticals | 6 Monate | 24 | EudraCT-2012-005588-28 |
| 2013 | Zosterimpfung und Grippeschutz | Glaxo Smith Kline Research & Development Ltd. | 1 Monat | 16 | EudraCT-2015-000965-30 |
| 2013 | COPD | Almirall, Astra Zeneca | 3 Monate | 20 | EudraCT-2013-000116-14 |
| 2014 | Reizdarmsyndrom | Menarini | 6 Monate | 15 | EudraCT-2013-000894-56 |
| 2014 | Binge Eating Disorder | Shire Development LLC | 1 Monat | 1 | EudraCT-2012-004457-88 |
| 2014 | Impfung gegen Clostridium difficile | Sanofi-Pasteur | 11 Monate | 6 | EudraCT-2013-000775-32 |
| 2014 | COPD | Novartis | 2 Monate | 21 | EudraCT-2013-001477-25 |
| 2014 | COPD | Glaxo Smith Kline Research & Development Ltd. | 6 Wochen | 12 | EudraCT-2011-005914-12 |
| 2014 | COPD | Glaxo Smith Kline Research & Development Ltd. | 2 Monate | 15 | EudraCT-2014-000611-14 |
| 2015 | Depression | Alkermes | 6 Monate | 48 | EudraCT-2014-000379-14 |
| 2015 | COPD | Astra Zeneca | 4 Monate | 11 | EudraCT-2014-004715-37 |
| 2015 | Raucherentwöhnung | Philip Morris | 1 Monat | 28 | EudraCT- 2013-002447-29 |
| 2015 | Fibromylagie | DaiichiSankyo Deutschland | 7 Monate | 28 | EudraCT-2013-005164-26 |
| 2015 | COPD | Pearl | 4 Monate | 29 | EudraCT-2014-004712-10 |
| 2016 | Akute Grippe | Vertex | 3 Monate | 1 | EudraCT- 2014-004068-39 |
| 2016 | Therapieresistente Depression | Janssen-Cilag | 10 Monate | 3 | EudraCT-2014-004587-38 |
| 2016 | Gräserpollenallergie | Allergopharma | 2 Monate | 33 | EudraCT- 2015-002409-13 |
| 2016 | Arthrose | PBB Entrepreneur Ltd. | 4 Monate | 56 | |
| 2016 | Asthma | Astra Zeneca | 1 Monat | 10 | EudraCT no. 2004-004042-41 |
| 2016 | Sodbrennen | Reckitt Benckiser | 5 Monate | 33 | EudraCT-2014-005261-69 |
| 2016 | Hyperlipidämie | Esperion Therapeutics | 6 Monate | 12 | EudraCT-2016-004115-12 |
| 2015 | Diabetes Mellitus | Astra Zeneca | 4 Monate | 9 | EudraCT-2015-002376-24 |
| 2016 | Nacken- und Rückenschmerz | Esperion Therapeutics, Boehringer Ingelheim | 5 Monate | 90 | EUdraCT-2015-000404-25 |
| 2016 | Schlafstörungen ab 55 Jahren | Esperion Therapeutics, Astra Zeneca | 5 Monate | 32 | EudraCT-2015-004136-36 |
| 2016 | Prodromales Alzheimer | Reckitt Benckiser, Boehringer Ingelheim | 1 Monat | 1 | EudraCT-2013-005031-24 |
| 2016 | Gedächtnisstörung | Pearl, Boehringer Ingelheim | 6 Monate | 16 | EudraCT-2013-005040-28 |
| 2016 | Verhütung | DaiichiSankyo Deutschland, Estetra SPRL | 5 Monate | 21 | EudraCT-2013-005164-26 |
| 2016 | COPD | Astra Zeneca | 3 Monate | 31 | EudraCT-2015-005444-33 |
| 2016 | Reizdarm | SymbioPharm | 5 Monate | 33 | EudraCT- 2011-004593-29 |
| 2016 | Onychomykose (Nagelpilz) | Polichem | 5 Monate | 60 | EudraCT-2015-000561-31 |
| 2016 | Reizdarm | Colibiogen | 4 Monate | 11 | EudraCT-2011-001743-78 |
| 2017 | Frühstadium Alzheimer-Erkrankung | Biogen | 18 Monate | 55 |